Table 3. Associations of GGT/HDL-C ratio with prevalence of NAFLD/MS by multivariate regression analyses.
| Model | NAFLD | MS | |||
|---|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | ||
| 1 | 1.017 (1.014–1.020) | <0.001 | 1.021 (1.018–1.024) | <0.001 | |
| 2 | 1.013 (1.010–1.016) | <0.001 | 1.023 (1.019–1.026) | <0.001 | |
| 3 | 1.011 (1.008–1.014) | <0.001 | 1.022 (1.018–1.028) | <0.001 | |
| 4 | 1.004 (1.001–1.007) | 0.006 | 1.004 (1.001–1.008) | 0.026 | |
| 5 | 1.003 (1.001–1.006) | 0.037 | 1.003 (1.000–1.007) | 0.084 | |
Adjusted model 1: Age, WC, BMI, SBP, DBP, sex, and smoking (baseline indexes); model 2: model 1 + ALP, AST, and ALT (liver markers); model 3: model 2 + Cr and UA (kidney markers); model 4: model 3 + TC, TG, and LDL-C (lipid markers); model 5: model 4 + HOMA-IR. NAFLD, nonalcoholic fatty liver disease; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; WC, waist circumstance; MS, metabolic syndrome; GGT, γ-glutamyl transpeptidase; HDL-C, high-density lipoprotein cholesterol; GGT/HDL-C, GGT/HDL-C ratio.